Funding sources This work was supported by the Network Epidermolysis bullosa grant from the Federal Ministry for Education and Research (BMBF) to L.B.-T., the Excellence Initiative of the German Federal and State Governments and Freiburg Institute for Advanced Studies, School of Life Sciences to L.B.-T. and by the K. Kriezis scholarship from the National and Kapodistrian University of Athens to D.K.
Phenotypic spectrum of epidermolysis bullosa associated with α6β4 integrin mutations
Article first published online: 8 JUL 2013
© 2013 The Authors BJD © 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 1, pages 115–124, July 2013
How to Cite
Schumann, H., Kiritsi, D., Pigors, M., Hausser, I., Kohlhase, J., Peters, J., Ott, H., Hyla-Klekot, L., Gacka, E., Sieron, A.L., Valari, M., Bruckner-Tuderman, L. and Has, C. (2013), Phenotypic spectrum of epidermolysis bullosa associated with α6β4 integrin mutations. British Journal of Dermatology, 169: 115–124. doi: 10.1111/bjd.12317
Conflicts of interest None declared.
- Issue published online: 8 JUL 2013
- Article first published online: 8 JUL 2013
- Accepted manuscript online: 17 MAR 2013 11:39PM EST
- Manuscript Accepted: 12 MAR 2013
- Federal Ministry for Education and Research
- Excellence Initiative of the German Federal and State Governments and Freiburg Institute
- National and Kapodistrian University of Athens
Integrin α6β4 is a transmembrane receptor and a key component of the hemidesmosome anchoring complex. It is involved in cell–matrix adhesion and signalling in various tissues. Mutations in the ITGA6 and ITGB4 genes coding for α6β4 integrin compromise dermal–epidermal adhesion and are associated with skin blistering and pyloric atresia (PA), a disorder known as epidermolysis bullosa with PA (EB-PA).
To elucidate the molecular pathology of skin fragility in eight cases, disclose the underlying ITGA6 and ITGB4 mutations and study genotype–phenotype correlations.
DNA was isolated from ethylenediaminetetraacetic acid–blood samples, and the coding exons and exon–intron boundaries of ITGA6 and ITGB4 were amplified by polymerase chain reaction (PCR), and directly sequenced. Skin samples were submitted to immunofluorescence mapping with antibodies to adhesion proteins of the dermal–epidermal junction. Primary keratinocytes were isolated, and used for RNA and protein extraction, reverse transcription PCR and immunoblotting. Ultrastructural analysis of the skin was performed in one patient.
We disclose 10 novel mutations, one in ITGA6 and nine in ITGB4. Skin cleavage was either intraepidermal or junctional. Lethal outcome and PA correlated with loss-of-function mutations in two cases. Solely mild skin involvement was associated with deletion of the C-terminus of β4 integrin. Combinations of missense, nonsense or frameshift mutations caused severe urinary tract involvement in addition to skin fragility in five cases.
The present study reveals novel ITGA6 and ITGB4 gene mutations and supports previous reports showing that the phenotype may lack PA and be limited to skin and nail involvement. In four out of six cases of EB-PA, life expectancy was not impaired. A high frequency of urinary tract involvement was found in this study, and represented the main cause of morbidity. Low levels of β4 integrin expression were compatible with hemidesmosomal integrity and a mild skin phenotype.